Peter Park‘s Park West Asset Management has recently reported its position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) through a 13G filing with the Securities and Exchange Commission. According to the filing, Park West owns 690,000 shares of Eagle Pharmaceutical and the stake, which is passive by nature, amasses 4.4% of the company’s outstanding common stock.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Park West Asset Management LLC | 690,000 | 0 | 690,000 | 0 | 690,000 | 4.4% |
| Peter S. Park | 690,000 | 0 | 690,000 | 0 | 690,000 | 4.4% |
Peter S. Park
Park West Asset Management We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9 SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
| EAGLE PHARMACEUTICALS, INC. |
| (Name of Issuer) |
| COMMON STOCK, $0.001 PAR VALUE PER SHARE |
| (Title of Class of Securities) |
| 269796108 |
| (CUSIP Number) |
| December 31, 2015 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9
